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ABSTRACT 
During the last decade, numerous studies have associated genetic 
variations in complement components and regulators with a number of chronic 
and infectious diseases. The functional characterization of these complement 
protein variants, in addition to recent structural advances in understanding of 
the assembly, activation and regulation of the AP C3 convertase, have provided 
important insights into the pathogenic mechanisms involved in some of these 
complement related disorders. This knowledge has identified potential targets 
for complement inhibitory therapies which are demonstrating efficacy and 
generating considerable expectation in changing the natural history of these 
diseases. Comprehensive understanding of the genetic and non-genetic risk 
factors contributing to these disorders will also result in targeting of the right 
patient groups in a stratified medicine approach through better diagnostics and 
individually tailored treatments, thereby improving management of patients.  
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The complement system 
Complement is a major component of innate immunity with crucial roles 
in microbial killing, apoptotic cell clearance, immune complex handling and 
modulation of adaptive immune responses (Ricklin, et al., 2010). Complement 
works as an amplification cascade, initiated through either the classical pathway 
(CP), the lectin pathway (LP) or the alternative pathway (AP). Activation of 
complement results in the formation of unstable protease complexes, named C3 
convertases (C3bBb in the AP; C4b2a in the CP/LP), which catalyze the central 
and most important step of complement activation: the cleavage of C3 to 
generate the activated fragment, C3b. When nascent C3b is generated, a 
reactive thioester is exposed which is attacked by nucleophiles (such as amine 
groups) on adjacent surfaces, resulting in covalent binding of C3b to the target 
surface, marking it for destruction and initiating inflammation at the site of 
activation. 
The AP is critical for efficient activation regardless of the trigger because 
it amplifies the response. In contrast to the CP and LP where activation is 
triggered by immune complexes and bacterial mannose groups respectively, the 
AP is intrinsically active. Spontaneous activation of C3 in plasma occurs 
through the “tick-over” mechanism, which is initiated by the generation of a fluid 
phase C3b-like molecule, called C3i or C3(H2O), by aqueous hydrolysis of the 
internal C3 thioester  (Pangburn, et al., 1981). Activation of C3 may also occur 
by continuous low rate cleavage of C3 to C3b by plasma proteases. The 
balance between the rate at which the initial trigger is amplified and the degree 
to which C3b and the AP C3-convertases are inactivated determines the 
progression of the complement cascade to cell damage and death. Foreign 
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substances on microbial pathogens, antibodies, or mannan, tip the balance in 
favour of amplification, causing target opsonisation (Lachmann, 2009). The 
positive regulator, properdin, stabilizes the AP C3-convertase and serves as a 
focal point for promoting local amplification of complement (Kemper, et al., 
2010). The terminal pathway fires when the AP C3-convertase incorporates one 
additional C3b molecule, which creates the C5-convertase and switches 
substrate specificity from C3 to C5, a C3 homologue that lacks the thioester. C5 
cleavage triggers inflammation and leukocyte recruitment through production of 
C5a, and initiation of membrane attack complex (MAC) formation. The MAC 
contains C5b plus the complement components C6, C7, C8 and C9, and lyses 
cells by punching holes through the membrane (Muller-Eberhard, 1985). 
Accelerated dissociation of the AP C3 convertase and inactivation of C3b 
are critical steps to maintain complement homeostasis and to prevent non-
specific damage to self-cellular components when complement is activated. 
These activities are performed primarily by factor H (fH), in collaboration with 
the plasma serine protease factor I (fI) (Rodriguez de Cordoba, et al., 2004). FH 
is an abundant plasma protein (0.2-0.5g/l) with an elongated structure 
presenting several binding sites for C3b and glycosaminoglycans (GAGs) along 
its length.  The GAG-binding domains are key to protection of self-tissues as 
they locate fH to cell membranes where it dissociates deposited AP 
convertases and inactivates C3b.  Self-tissues are also protected by 
membrane-bound proteins that restrict complement activation in three ways: i) 
acting as cofactor for proteolytic inactivation of C3b by fI; ii) accelerating 
convertase dissociation; iii) inhibiting MAC formation (Figure 1).  Thus, in health, 
spontaneous activation of C3 in plasma is kept at a low level and further 
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complement activation and C3b deposition is restricted to targets lacking 
surface regulators. 
 
Genotype-phenotype correlations between complement and disease  
The relationship between complement deficiencies and pathology has 
been recognized for over 50 years and complement is firmly implicated in a long 
list of diseases, responsible for sustaining a 'vicious cycle' of inflammation and 
perpetuating tissue damage.  However, completion of the Human Genome 
Project during the last decade has catalysed expansion of this long list as 
studies have associated specific mutations and/or polymorphisms in 
complement components and regulators with predisposition to numerous rare 
and prevalent chronic inflammatory diseases, and with susceptibility to infection. 
Diseases associated with complement are genetically complex in that they are 
commonly associated with mutations and/or polymorphisms in more than one 
complement component. In addition, they are multifactorial in the sense that 
non-genetic risk factors and factors unrelated to complement also contribute to 
disease development and progression. Importantly, it is not unusual that the 
same gene or combination of genes is involved in several distinct pathological 
entities, perhaps because of the impact of non-complement drivers. Table 1 
summarizes the complement genes associated with a number of different renal 
and ocular diseases to illustrate the complexities.  
The functional characterization of disease-associated complement 
genetic variations has improved our understanding of these genetically complex 
diseases and, in some cases, unravelled the role that complement plays in 
pathogenesis. Complement dysregulation is a unifying pathogenic feature in 
  6 
many of these diseases.  Remarkably, functional analyses have shown that 
there is a strong correlation between mutations causing particular functional 
alterations in a complement protein and specific susceptibility to a particular 
disease. A comprehensive understanding of the genetic component 
predisposing to the pathology and its functional consequences at the protein 
level is therefore critical to guide appropriate diagnostics and effective treatment 
in complement-related disorders.  
 
1) Mutations in the C-terminal region of fH are prototypical in aHUS. 
Hemolytic uremic syndrome (HUS) is a rare, life threatening disease 
characterized by thrombocytopenia, Coombs test negative microangiopathic 
haemolytic anemia and acute renal failure. The commonest form of HUS follows 
a diarrhoeal prodrome and is associated with infections involving shiga-toxin 
producing E. coli strains (STEC-HUS; EHEC-HUS). However, five to ten 
percent of HUS patients lack an association with diarrhoea. This atypical form of 
HUS (aHUS), with an incidence of about 3/106 per year and a prevalence of 
1/105 children in the whole European Union, has the poorest long-term 
prognosis. Recurrences in aHUS are common with a mortality rate that 
approaches 30% (Noris and Remuzzi, 2005). 
Although fH deficiencies were implicated in the pathogenesis of aHUS in 
the early 1980’s, it was the pioneering work by Warwicker et al., published in 
1998, which identified the association of the RCA gene cluster with aHUS 
(Warwicker, et al., 1998). These findings triggered a number of seminal studies 
that delineated the genetic predisposition to aHUS and provided fundamental 
insights into its pathogenic mechanisms, changing the earlier perception that 
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aHUS was a pathology related to hypocomplementemia (lack of complement) to 
the realization that the disorder was caused by dysregulated complement 
activation (Caprioli, et al., 2001, Perez-Caballero, et al., 2001, Richards, et al., 
2001). 
aHUS is associated with mutations or polymorphisms in the genes 
encoding the complement regulatory proteins fH (CFH) (Caprioli, et al., 2001, 
Caprioli, et al., 2003, Perez-Caballero, et al., 2001, Richards, et al., 2001, 
Warwicker, et al., 1998) membrane cofactor protein (MCP) (Esparza-Gordillo, et 
al., 2005, Noris, et al., 2003, Richards, et al., 2003) and factor I (CFI) 
(Fremeaux-Bacchi, et al., 2004); (Kavanagh, et al., 2005), and with mutations in 
the genes encoding complement components factor B (CFB) (Goicoechea de 
Jorge, et al., 2007) and C3 (C3) (Fremeaux-Bacchi, et al., 2008). Mutations in 
thrombomodulin (THBD) have also been described in association with aHUS 
(Delvaeye et al, 2009). Missense mutations in CFH are prototypical of aHUS 
and the most prevalent genetic alteration, present in approximately 25% of the 
aHUS patients in all series. aHUS-associated CFH mutations cluster in the C-
terminus of the protein, a region that is critical to the capacity of fH to bind cell 
surfaces and control local activation of complement (Figure 2). Carriers of these 
CFH mutations express fH molecules that possess normal regulatory activity in 
plasma but a limited capacity to bind and protect cells from complement lysis 
(Manuelian, et al., 2003, Perez-Caballero, et al., 2001, Sanchez-Corral, et al., 
2004, Sanchez-Corral, et al., 2002). It is therefore the combination of an active 
complement system in plasma and a defective protection of cellular surfaces 
that determines the development of aHUS. These findings fit well with the 
identification of aHUS-associated loss-of-function mutations in MCP and CFI; 
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these mutations also lead to decreased protection of host cells from 
complement lysis without affecting significantly complement homeostasis in 
plasma (Figure 3) (Atkinson, et al., 2005). 
The penetrance of disease in carriers of aHUS-associated mutations is 
approximately 50%, indicating that additional genetic and environmental factors 
contribute to disease development. In fact, it is now well documented that 
concurrence of different genetic risk factors greatly influences predisposition to 
aHUS in carriers of mutations in CFH, MCP, CFI and CFB (Esparza-Gordillo, et 
al., 2005, Esparza-Gordillo, et al., 2006, Goicoechea de Jorge, et al., 2007, 
Martinez-Barricarte, et al., 2008, Neumann, et al., 2003). Among these 
additional risk factors are two relatively frequent CFH and MCP haplotypes that 
may determine decreased expression of fH and MCP respectively (Caprioli, et 
al., 2003, Esparza-Gordillo, et al., 2005, Liszewski, et al., 2007). 
Factor B and C3 gain-of-function mutations are characteristic of a 
subgroup of aHUS patients showing persistent activation of the AP in plasma 
(Fremeaux-Bacchi, et al., 2008, Goicoechea de Jorge, et al., 2007, Roumenina, 
et al., 2012). From a pathogenic point of view it is intriguing that these fB and 
C3 gain-of-function mutations, decreasing C3 plasma levels and causing 
different degrees of hypocomplementemia, are nevertheless associated with 
aHUS. One possible explanation is that increased complement activation 
caused by gain-of-function mutations, a situation that may be similar to that 
occurring during infection, coincides with an additional aHUS risk factor 
impairing surface protection. In support of this possibility, we note that carriers 
of fB or C3 gain-of-function mutations that develop aHUS are also carriers of 
the MCP risk haplotype (Goicoechea de Jorge, et al., 2007, Roumenina, et al., 
  9 
2012). In the case of mutations in C3 associated with aHUS, different 
experimental approaches have shown that these mutations alter the sensitivity 
of C3b to inactivation by fH and MCP and/or change the susceptibility of the AP 
C3 convertase to accelerated decay by fH and DAF ((Fremeaux-Bacchi, et al., 
2008, Roumenina, et al., 2012); our unpublished results). 
Taken together, genetic and functional analyses have established that 
aHUS involves complement AP dysregulation and develops as a consequence 
of defective protection of cellular surfaces from complement activation. Multiple 
hits, involving plasma and membrane-associated complement regulatory 
proteins as well as complement components, are likely required to cause 
dysregulation and significantly impair protection to host tissues. Environmental 
factors that activate complement likely modulate genetic predisposition and are 
also very important in aHUS. Infection, immunosuppressive drugs, cancer 
therapies, oral contraceptives, pregnancy and childbirth are important factors 
that trigger attacks of aHUS in some patients. In carriers of multiple strong 
aHUS genetic risk factors the contribution of the environment is probably minor. 
On the other hand, in those with a low genetic predisposition, strong 
environmental factors may still precipitate disease. Whether this scenario 
explains the severe or fatal outcome of a small proportion of individuals with the 
more common diarrhoea-associated STEC-HUS remains to be determined 
(Fang et al., 2008).  
 
2) Complement fluid phase dysregulation and DDD 
Dense deposit disease (DDD) is a rare form of glomerulonephritis which 
affects both children and young adults and frequently results in end-stage renal 
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disease (ESRD) (Smith, et al., 2011). The morphologic hallmark of DDD is the 
presence of electron-dense deposits within the glomerular basement membrane 
(GBM), as resolved by electron microscopy. The chemical composition of the 
dense deposits is largely unknown, although IgG is absent from them and other 
regions of the glomerulus, which excludes a role for immune complexes in 
dense deposit formation. DDD is associated with complement abnormalities 
which include persistent reduction of C3 serum levels and intense deposition of 
C3 fragments in GBM. The majority of DDD patients have C3 nephritic factors 
(C3NeF), autoantibodies against the AP convertase, in their plasma that may be 
causative. Familial cases of DDD are rare but extremely informative. The 
functional characterization of human DDD-associated fH and C3 mutations 
(Licht, et al., 2006, Martinez-Barricarte, et al., 2010) and previous studies in 
animal models (Hogasen, et al., 1995, Pickering, et al., 2002) have provided 
conclusive evidence that fluid phase complement dysregulation, resulting in the 
continuous activation of C3 in plasma, plays a major role in DDD pathogenesis 
(Figure 3). 
Recently, the CFH genotype-phenotype correlation was formally 
established in a murine model. Factor H-deficient mice (Cfh-/-) develop DDD as 
a consequence of massive activation of C3 (Pickering, et al., 2002). These mice 
present very low levels of C3 and complement activity in plasma. Introduction 
into Cfh-/- mice of a transgenic fH molecule (FH16-20) that mimics the fH 
mutations found in aHUS patients restored the C3 levels and the complement 
activity in the plasma of these fH-deficient animals. As a result, Cfh-/- FH16-20 
animals switch their disease phenotype from DDD to aHUS (Pickering, et al., 
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2007), validating the conclusion that the combination of active complement in 
plasma with a decreased protection of cell surfaces leads to aHUS.  
Further studies are still necessary to unravel the precise molecular 
events that lead to the development of DDD. An important step has been taken 
with the creation of fH/fI double knockout mice; absence of fI protected the fH-
deficient mice from developing DDD, demonstrating that fluid phase activation 
of C3 and generation of iC3b is critical in pathogenesis in DDD (Rose, et al., 
2008).  
While mutations at the C-terminus of fH are typical of aHUS and 
complete functional deficiency of fH is the prototypic mutation associated with 
DDD, there are both aHUS and DDD patients with partial fH deficiencies due to 
mutations in the CFH gene (Dragon-Durey, et al., 2004, Landau, et al., 2001, 
Levy, et al., 1986, Ohali, et al., 1998, Smith, et al., 2007). Overlap between 
syndromes illustrates their genetic complexity. Additional genetic and 
environmental factors likely provide the context that decides the pathological 
outcome in partial fH deficiencies. For example, concurrence of partial fH 
deficiencies with other mutations or polymorphisms that decrease protection to 
host cells will result in aHUS (Hakobyan, et al., 2010, Perez-Caballero, et al., 
2001, Sanchez-Corral, et al., 2002), whereas the coincidence of partial fH 
deficiencies with strong complement activators like C3NeF will trigger DDD 
(Licht, et al., 2006). DDD is part of a large and heterogeneous group of kidney 
pathologies, the C3 glomerulonephropathies (C3-GN), with distinct patterns of 
glomerular inflammation, mediated by complement dysregulation and 
characterized by glomerular deposition of C3 (Fakhouri, et al., 2010). C3Nef are 
also found in some non-DDD C3-GN patients, often with mutations in CFI and 
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CFH (Servais et al., 2012), further illustrating the overlap between these 
complement dysregulation disorders and the requirement of particular 
combinations to trigger specific pathologies.    
 
  
3) AMD is an exemplar complex genetic disorder involving common 
complement polymorphisms. 
Age-related macular degeneration (AMD), the commonest cause of 
blindness in the western world, shows a very high (40-70%) and well 
characterized genetic component, including a large set of common 
polymorphisms in complement components and regulators (Gorin, 2012). 
Retinal drusen, the hallmark of AMD, was known to contain complement 
proteins based on immunohistochemical and biochemical analysis, a finding 
that initially had attracted little attention (Hageman and Mullins, 1999). A 
quantum shift in interest occurred in 2005 when several papers reported 
candidate region studies and whole-genome association analyses that 
implicated the region encoding fH at 1q31 as a major susceptibility locus for 
AMD (Edwards, et al., 2005, Hageman, et al., 2005, Haines, et al., 2005, Klein, 
et al., 2005). The CFHY402H allele (rs1061170) conferred a significantly 
increased risk of AMD with an odds ratio (OR) between 2.1 and 7.4. The 
association of a CFH polymorphism with AMD strengthened the implication of 
complement in the pathogenesis of AMD and prompted subsequent candidate 
gene studies that identified additional associations (protective and non-
protective) of complement genes, including CFI, C3, C2/CFB, CFHR3/CFHR1 
and C7, with AMD (Dinu, et al., 2007, Fagerness, et al., 2009, Gold, et al., 2006, 
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Hughes, et al., 2006, Yates, et al., 2007). Together, these genetic data reinforce 
the concept that complement dysregulation is a major player in the 
pathogenesis of AMD.  
The mechanism by which complement polymorphisms impact AMD risk 
is as yet unsolved, although it is clear that different polymorphisms can act 
additively to cause local complement dysregulation and pathology (Heurich, et 
al., 2011, Maller, et al., 2006). Some of them, like the fH62I (rs800292), fB32Q 
(rs641153) and C3102G (rs2230199) variants, alter AP convertase formation or 
regulation (Heurich, et al., 2011, Montes, et al., 2009, Tortajada, et al., 2009), 
while others like fH402H (rs1061170) may result in failure to recruit fH to sites 
where complement is activated by the accumulation of endogenous 
complement-activating compounds. For example, it has been recently reported 
that the fH402H variant fails to bind malondialdehyde, a common lipid 
peroxidation product found in the aged retina and implicated in AMD 
(Weismann, et al., 2011). 
The association of AMD with the 1q31 locus is complicated by the large 
number of polymorphisms within these regions and the strong linkage 
disequilibrium between them (Figure 4A). As a consequence, it is often difficult 
to ascribe risk to a specific protein or polymorphism in the inherited set – the 
haplotype. For example, the FHY402H polymorphism (rs1061170) is part of the 
common H1 haplotype of the CFH gene (CFH) that encompasses several other 
linked polymorphisms in fH and fH-related (FHR) proteins (Hageman, et al., 
2006). These include a recently described common allelic variation in the 
CFHR1 gene; the *A variant of the FHR-1 protein, risk for AMD, differs from the 
*B variant by three amino acids (Abarrategui-Garrido, et al., 2009, Martinez-
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Barricarte, et al., 2012). A second CFH haplotype, H2, is protective for AMD 
and includes the FHV62I (rs800292; odds ratio (OR) 0.54) polymorphism and a 
non-coding intronic SNP, while a second AMD-protective haplotype, H4, 
includes the deletion, common in Caucasians, of the CFHR1 and CFHR3 genes 
encoding the proteins FHR-1 and FHR-3 (Hageman, et al., 2005, Hughes, et al., 
2006). In order to prove that a particular protein variant in the haplotype is 
responsible for altered disease risk it is necessary to demonstrate that the 
polymorphism has an effect on protein function or production that is compatible 
with the observed change in disease risk. Although this has now been achieved 
for some of the disease-associated complement polymorphisms, the task is far 
from complete; for example, the functional effect of the FHR-1 polymorphism 
described above and its contribution to AMD risk in the H1 haplotype is 
unknown.  Recently, the prevalent aHUS-associated FHR1210C mutation 
(Martinez-Barricarte et al., 2008) has been associated with early onset of AMD 
(Raychaudhuri et al., 2011), a remarkable finding illustrating that AMD has links 
not only with DDD, but also with other complement dysregulation disorders, 
including aHUS. As discussed above for partial fH deficiencies, additional 
genetic and environmental factors likely provide the context that decides the 
pathological outcome in carriers of the FHR1210C mutation. 
 
 
4) CFHR genes, FHR proteins and disease risk 
The family of fH-related proteins (FHRs), revealed over the last two 
decades predominantly by the work of Zipfel and co-workers (Jozsi and Zipfel, 
2008) are somewhat neglected, in large part because they are compared to fH 
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itself (around 500mg/l in plasma), relatively minor plasma components with 
concentrations in the range 5 to 50mg/l. The genes CFHR3, CFHR1, CFHR4, 
CFHR2 and CFHR5 encoding these FHR proteins are located downstream and 
closely linked to the CFH gene (Figure 4A). Genomic and sequence analyses of 
the CFH-CFHR1-5 gene region suggest that the CFHR genes originated from 
the CFH gene by tandem duplication events (Perez-Caballero, et al., 2001).  All 
the CFHR genes retained, with different degrees of sequence conservation, the 
exons that encode the C-terminal region of fH (Figure 4B), explaining the 
capacity of most FHR proteins to interact with C3b, iC3b, C3dg and 
carbohydrates (Jozsi and Zipfel, 2008, Skerka and Zipfel, 2008, Zipfel, et al., 
1999). None of the FHR proteins contain regions homologous with the 
complement regulatory SCRs 1-4 of fH; however, weak cofactor and/or decay 
accelerating activities have been reported for some of them.  Although the 
physiological relevance of these interactions and activities is not yet fully clear, 
it is generally accepted that the FHRs influence complement activation and 
regulation via their interaction with C3b and C3dg fragments and carbohydrates 
on particular surfaces. How FHRs exert this influence is still controversial.  
It has been suggested that some FHR proteins (like FHR3 and FHR1) 
modulate complement regulation, competing with fH for binding to C3b and 
interfering with fH complement regulatory activities (Fritsche, et al., 2010, 
Heinen, et al., 2009). An argument against this is the relatively low plasma 
concentrations of the FHR proteins compared to fH noted above. However, a 
differential binding specificity of the FHRs and fH proteins for C3b in the context 
of particular carbohydrates may increase the affinity of these FHR molecules 
locally to allow them to compete efficiently with fH. The hybrid CFH::CFHR1 
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genes found associated with aHUS may support this possibility ((Venables, et 
al., 2006); see below). An interesting, and contrasting alternative to the 
competition theory is the suggestion that FHR4A, FHR4B and FHR3 regulate 
complement activation by enhancing the cofactor activity of fH (Hebecker and 
Jozsi, 2012, Hellwage, et al., 1999). 
Experimental evidence has accumulates in recent years supporting the 
contention that some FHRs have endogenous complement regulatory functions. 
FHR1 is reported to act downstream of fH and inhibit the C5-convertase, while 
FHR3 has cofactor activity for factor I-mediated inactivation of C3b (Fritsche, et 
al., 2010, Heinen, et al., 2009). Cofactor activity has also been reported for the 
FHR4B isoform (Hellwage, et al., 1999)  and for FHR5 (McRae, et al., 2005); 
however, these activities are weak and their physiological relevance has been 
questioned (Hebecker and Jozsi, 2012). Finally, it was recently suggested that 
the FHRs may promote complement activation; the A isoform of FHR4 
enhanced complement activation via its interaction with C3b (Hebecker and 
Jozsi, 2012). 
The CFH-CFHR1-5 gene region shows significant genetic variability. In 
addition to conventional polymorphism due to sequence variations, the 
presence within the region of large genomic duplications (ranging in size from 
1.2 to 38 kb) makes the region highly prone to genomic rearrangements through 
gene conversion and non-homologous recombination (Figure 4A) (Perez-
Caballero, et al., 2001). These rearrangements are readily identified by MLPA 
(Multiplex Ligation-dependent Probe Amplification) technologies (Venables, et 
al., 2006), CNV microarrays or western blots (Abarrategui-Garrido, et al., 2009, 
Zipfel, et al., 2007). Notably, several rearrangements have been identified in 
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recent years associated with different pathologies involving complement 
dysregulation. They are remarkable “experiments of nature” that may help to 
clarify some of the current uncertainties regarding the function of the FHR 
proteins (Table 2). 
A very prevalent rearrangement in this region, a true common 
polymorphism in humans, is the deletion of the CFHR1 and CFHR3 genes, 
likely resulting from a single non-homologous recombination event between a 
duplicated region downstream of the CFH and CFHR1 genes, which became 
fixed early in human evolution, likely implying a selective advantage (Hageman, 
et al., 2006). The deletion of the CFHR1 and CFHR3 genes is included in a 
single extended CFH-CFHRs haplotype, H4, that associates with lower risk of 
AMD (Hughes, et al., 2006) and IgA nephropathy (Gharavi, et al., 2011) and 
increased risk of SLE (Zhao, et al., 2011). This remarkable finding suggests that 
binding of these FHR proteins, and capacity to regulate complement, directly or 
by complementing or competing with fH, can be beneficial or detrimental 
depending on the circumstances.  
The deletion of the CFHR1 and CFHR3 genes is likely also protective in 
aHUS (Abarrategui-Garrido, et al., 2009, Martinez-Barricarte, et al., 2012); 
however, the frequency of homozygosity for the CFHR3-CFHR1 deletion is 
increased in aHUS as a consequence of the association between complete 
deficiency of the FHR1 protein and the generation of anti-fH autoantibodies 
(Abarrategui-Garrido, et al., 2009, Dragon-Durey, et al., 2009, Jozsi, et al., 2008, 
Moore, et al., 2010, Zipfel, et al., 2007). This is an intriguing association for 
which there is no clear explanation. Importantly, the anti-fH autoantibodies 
recognize the C-terminus of fH, the region critical for the development of aHUS 
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that is nearly identical in FHR1; not surprisingly, the autoantibodies cross-react 
with FHR1. It has been suggested that deficiency of FHR1 may result in a 
failure of central and/or peripheral tolerance to the homologous region in fH, but 
there are other possibilities, including cross-reactivity with microbial antigens.  
Another relatively frequent rearrangement in the CFH-CFHR region 
involves an unequal crossover between homologous regions in the 3’ ends of 
CFHR3 and CFHR4 genes that specifically removes the CFHR1 and CFHR4 
genes. This deletion is also found in aHUS patients in association with anti-fH 
autoantibodies for the reasons indicated above (Abarrategui-Garrido, et al., 
2009), and is also associated with C3-glomerulopathies (C3-GN). 
Most interesting are the various genomic rearrangements between the 3’ 
end exons of CFH and the homologous regions in CFHR1 or CFHR3, which 
have been associated with aHUS (Francis, et al., 2012, Venables, et al., 2006). 
All result in the generation of CFH::CFHR1 or CFH::CFHR3 hybrid genes that 
alter the C-terminal region of fH, further illustrating the remarkable correlation 
between C-terminal region deficits in fH and aHUS. On the other hand, the 
CFH::CFHR1 hybrid gene in which the C-terminal exons of fH have been 
replaced by those in FHR1 demonstrates that, despite their sequence 
similarities, the C-terminal regions of fH and FHR1 have distinct binding 
specificities and do not compete - at least not for substrates that are relevant in 
aHUS. 
A unique set of genomic rearrangements in the CFHRs gene region are 
found associated with C3-GN. The most remarkable of these involves the 
duplication of the first two SCRs of the FHR5 protein; this by itself defines a 
monogenic disorder endemic in Cyprus denominated FHR5 nephropathy 
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(Athanasiou, et al., 2011, Gale, et al., 2010, Gale and Pickering, 2011). Other 
rearrangements associated with C3-GN include a hybrid CFHR3::CFHR1 gene 
(Malik, et al., 2012) and an internal duplication of the FHR1 protein 
(Abarrategui-Garrido, et al., 2010). The functional implications of these 
rearrangements are currently being investigated; it is unclear whether they 
represent loss of function or gain of function mutations. 
Apart from these genomic mutations and polymorphisms, other disease-
associated polymorphisms in FHR proteins include the FHR-1*A/*B variant 
described above; possession of the *B variant is risk for aHUS, while 
possession of the *A variant is risk for AMD (Abarrategui-Garrido, et al., 2009, 
Martinez-Barricarte, et al., 2012), further emphasizing the dichotomy of 
complement regulation in these disorders. The *A  and *B variants differ by 
three amino acids with *B having higher homology with fH (Figure 4B); how 
these differences affect function remains unclear. Five different polymorphisms 
in the CFHR5 gene have been described and associated with risk of aHUS, 
DDD and AMD (Abrera-Abeleda, et al., 2011, Monteferrante, et al., 2007, 
Narendra, et al., 2009). 
The CFH-CFHRs genetic hotspot is an area in which we anticipate much 
more activity in the near future. It seems inevitable that other disease 
associated polymorphisms in this complex gene family will emerge and their 
functional characterization will resolve the mechanisms by which in health fH 
and the FHR proteins collaborate to control complement on different surfaces. 
 
The complotype 
1) A predictor of disease risk. 
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 The complotype describes the repertoire of inherited common 
polymorphisms in genes encoding complement proteins and regulators. This 
term was used originally to describe haplotypic combinations of genetic variants 
of MHC-linked complement genes (Alper, et al., 1986), but has been expanded 
recently to include variants in the whole complement system (Harris, et al., 
2012).  Functional analyses of polymorphic variants within the AP demonstrate 
that they work together to dictate the balance between activation and regulation, 
and thereby set the complement activating capacity of an individual (Heurich, et 
al., 2011, Montes, et al., 2009, Tortajada, et al., 2009). Inheritance of more 
active variants of AP components (C3, fB) or less active variants of regulators 
(fH, fI, MCP) swings the balance in favour of AP activation and inflammation, 
while inheritance of less active variants of components and more active 
regulators dictates less AP activation and inflammation.  The functional effect of 
each AP polymorphic variant is small, as might be expected from a common 
polymorphism.  However, their combined effects can be striking, particularly 
when they directly influence the AP amplification loop, the means by which 
small activation triggers are massively amplified.  Common non-coding 
polymorphic variation also influences expression levels of complement proteins, 
adding an extra dimension to the concept of the complotype. 
The inherited pattern of complement variants, and the expression levels 
of these proteins, have direct effects on systemic activity and thus alter risk for 
pathologies driven by complement activation.  However, the contribution of the 
complotype to disease risk is complex – in addition to overall complement 
activity, the pattern of inherited variants influences development of pathology in 
different ways depending on the underlying disease mechanism (Table 1).  
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Genetic studies in AMD, DDD and aHUS described above, show that often 
multiple hits are needed to cause disease. For example, in aHUS, disease 
requires not only the disease-associated mutation in an AP protein, but also 
altered expression of another AP protein or a risk complotype (Esparza-Gordillo, 
et al., 2005, Hakobyan, et al., 2010).  Protein variants which are risk for aHUS, 
a disease caused by complement dysregulation at the cell surface, may not be 
risk for other pathologies caused primarily by dysregulation in the fluid phase. 
 
2) Molecular complotyping in complement dysregulation disorders. 
Molecular analyses provide most of the information required to define an 
individual’s complotype, although some aspects, for example plasma 
concentrations of components, can be ascertained only by protein assays.  
Complement molecular diagnostics contribute to identification and 
understanding of complement dysregulation disorders by providing basic 
information on complement mutations and polymorphisms, and by building from 
these datasets algorithms that are predictive of disease susceptibility, progress 
or response to therapy.  
In the simplest situation, a single complement gene or set of genes is 
demonstrated to be associated with development of a particular pathology; 
identification of the responsible complement protein mutations/polymorphisms 
and their effects on protein function then provides direct help in tailoring 
management and therapeutic strategies. Even this superficially simple task is 
often one of significant complexity. In the case of aHUS, for example, 
complotyping will include a search for mutations not just in the CFH gene, but 
also in MCP, CFI, CFB and C3 genes, by PCR exon amplification and DNA 
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sequencing, together with copy number variation (CNV) analysis of the CFH-
CFHRs gene region to identify genomic rearrangements, deletions and 
duplications. Thereafter, interpretation of the findings is not always 
straightforward, frequently requiring mutation segregation analysis between 
affected and unaffected family members, searches in the general population to 
identify and eliminate rare polymorphisms, and an analysis of the impact of the 
mutation on either protein expression or function (Tortajada, et al., 2012). 
Current technologies are limiting because of cost and time constraints in 
analysis of these numerous genes and interpretation of the variability of the 
complement components; however, recent advances in DNA sequencing 
technologies are generating enormous expectations in the community. Next-
generation sequencing and the continuously falling cost and increasing speed 
of sequencing will solve some of these problems by making it possible to 
undertake a complete characterization of genetic variability in all complement 
components in an individual at reasonable cost. These data will only be of value 
if linked to advanced informatics to identify relevant patterns and rationalize 
mutation analysis of the whole set of complement genes.  There will be a need 
to develop predictive algorithms, likely different for each disease, to estimate 
risk based on complotype, other genetic factors and environmental or other 
exogenous factors. An excellent example of this is the case of AMD where 
genetic variations in complement proteins are additive in their effects on 
disease susceptibility and interact strongly with other genetic and non-genetic 
factors (for example, smoking) (Hecker, et al., 2010, Heurich, et al., 2011, 
Martinez-Barricarte, et al., 2012, Reynolds, et al., 2009, Scholl, et al., 2008). 
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In the future, we predict that analysis of an individual’s complotype will be 
widely used, in conjunction with environmental and other known risk factors, to 
predict disease risk and course.  Complement quantitative traits must also be 
incorporated into the disease-predictive algorithms as complement protein 
levels show important inter-individual variability and are relatively stable 
characteristics with a high heritability (Buil, et al., 2010, Esparza-Gordillo, et al., 
2004, Sanchez-Corral, et al., 1995).  
A particular challenge is the identification of biomarkers that may help to 
anticipate development of the disease in predisposed individuals and be useful 
in monitoring disease activity and response to treatment in patients. 
Measurement of complement activation products is likely to be an important 
add-on to the genetically determined complotype in such analyses; even in 
isolation, measures of complement activation have been shown to be predictive 
of disease course in diseases as diverse as AMD and multiple sclerosis (MS) 
(Ingram, et al., 2012, Reynolds, et al., 2009, Scholl, et al., 2008, Smailhodzic, et 
al., 2012). Assay automation, multiplexing and other recent advances in -omics 
technologies has opened a window of opportunity for rapid and substantial 
progress in this area.  
 
3) The role of the complotype in patient stratification and choice of therapy. 
We are now in the age of stratified medicine, the stated goal of which is to 
deliver the right drug or other intervention to the right patient at the right time.  
The concept is built on understanding that the genetic makeup of an individual 
impacts their risk of developing a particular disease, their disease course and 
their response to therapies. Stratifying patients into groups based on likely 
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outcome and responsiveness to treatment will deliver better outcomes at lower 
cost because those most likely to respond are identified early and treated 
appropriately. For complement-mediated diseases, defining the complotype will 
be a key component of patient stratification and personalization of therapy. To 
take AMD as an example, individuals presenting with early disease would be 
complotyped using appropriate genetic (outlined above) and/or protein analyses, 
including measures of plasma levels of key components and activation products.  
Those with “high risk” complotypes, defined as carriers of multiple risk alleles 
(CFH-402H, CFH-62V, CFHR1*A, CFB-32R, C3-102G, others), particularly 
accompanied by evidence of complement activation, would be stratified for 
therapies targeting complement activation. Those with a low risk complotype 
and no evidence of ongoing complement activation would be stratified to other 
therapeutic options.  
Defining the complotype will also help evolve new therapeutic strategies in 
complex diseases where complement may play a role in a subset of patients.  
For example, MS is a highly complex disease that is currently impossible to 
treat (Compston and Coles, 2002). The disease is heterogeneous, likely 
representing a number of overlapping clinical entities, and the numerous 
failures of initially promising agents in clinical trials likely reflects this fact – 
some respond but most don’t.  Better stratification of MS patients into disease 
subgroups is essential for future drug development, not least because it will 
enable selection of appropriate patients into trials, and is attracting much effort. 
A role for complement in MS has been suggested for more than thirty years 
based on studies in animal models (Ingram, et al., 2009, Linington, et al., 1989, 
Morariu and Dalmasso, 1978); however, data from patients has been 
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inconsistent, likely reflecting disease heterogeneity (Lassmann, 2004). Based 
upon pathological and clinical evidence, Lassmann described four subgroups in 
MS that differed in the underlying pathology; one of these, Type II – some 30% 
of patients, involved abundant complement activation, but the other subgroups 
did not (Lucchinetti, et al., 2000). Because this stratification required access to 
brain tissue – biopsy or autopsy – it has been of little value clinically. However, 
several recent reports describing measurement of complement proteins and 
activation products, in CSF or plasma, as biomarkers of disease opens up the 
real prospect of identifying those patients most likely to benefit for inclusion in 
trials of anti-complement drugs (Ingram, et al., 2012, Ingram, et al., 2010, 
Ingram, et al., 2010). Although some individual complement polymorphisms 
have been explored as potential susceptibility factors, there has been no broad 
brush analysis of complement genetic associations with MS; a combination of 
proteomic and genomic complotype analyses might provide a tractable way of 
identifying the complement-driven subset, enabling targeted trials of anti-
complement therapies.  Similar issues pertain in many other chronic 
inflammatory diseases. In AD, complement has been implicated both as a 
protective and destructive player (Bonifati and Kishore, 2007, Veerhuis, et al., 
2011). Evidence for complement activation is found in tissues, CSF and plasma 
but no clear picture of how complement influences the disease has emerged.  
Complotyping, particularly in early disease or in those at high risk of developing 
disease (mild cognitive decline for example), may be helpful in identifying 
subgroups or stages of the disease that might benefit from anti-complement 
therapy, 
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4) The complotype defines disease-driving complement pathways. 
Analysis of the complotype will, by identifying which complement pathway 
is most important in driving dysregulation and pathology in a particular disease, 
aid choice of therapy.  Diseases of AP dysregulation, linked to mutations in AP 
components or regulators, are most likely to be ameliorated by drugs that target 
the AP, while diseases in which the CP is the driver will be best treated using 
CP inhibitory drugs.  Hereditary angioedema (HAE) provides the perfect 
example of the latter scenario. Mutations in the C1inh gene result in deficiency 
of C1inh and dysregulation of the CP; replacement therapy using purified C1inh 
restores homeostasis (Cicardi and Zanichelli, 2010).  Surprisingly, despite its 
long and successful record of use in HAE, C1inh therapy has not been used for 
other disease of complement dysregulation – this may in part be because it has 
not been clear which diseases are CP-driven. In contrast, a much more recently 
developed complement therapeutic is finding broader use. Eculizumab™, a 
blocking monoclonal antibody against human C5 that inhibits C5a and MAC 
generation (Rother, et al., 2007), was first successfully used for treatment of 
paroxysmal nocturnal hemoglobinuria (Brodsky, 2009), a hemolytic and 
thrombotic disorder caused by deficiency of GPI-linked proteins (including 
complement regulators CD55 and CD59) on blood cells (Takeda, et al., 1993). 
Erythrocytes, deficient in surface regulators, activate complement, probably via 
the AP, and are lysed by MAC formation; blocking C5 prevents MAC formation 
and rescues patients from dependence on transfusions. Eculizumab was first 
suggested as a therapy for DDD in 2007 (Smith, et al., 2007), and soon after 
tested with good effect in aHUS patients to prevent relapses of the disease and 
recurrences after transplantation (Mache, et al., 2009, Nurnberger, et al., 2009). 
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Based on the excellent results obtained in phase II clinical trials during 2009-10, 
Eculizumab was approved by the US Food and Drugs Administration and the 
European Medicines Agency and has rapidly become the accepted therapy in 
patients with aHUS, both as a rescue therapy in acute episodes and as 
prophylaxis in labile patients and following renal transplant.  
Isolated case reports describe a heterogeneous response in cases of C3-
GN, including DDD, indicating that further research is needed to define the 
subgroup of C3-GN patients in whom Eculizumab therapy may be effective 
(Bomback, et al., 2012, Daina, et al., 2012, Vivarelli, et al., 2012). A Phase II 
study of systemic Eculizumab therapy in dry AMD is scheduled to report July 
2012. 
It is at first sight surprising that a therapy targeting the terminal pathway 
would be effective in diseases of AP dysregulation. C3 convertase assembly 
and C3 fragment deposition will continue unhampered, provoking the 
conclusion that C5a and MAC are major drivers of pathology in these diseases. 
It is not yet clear whether deposition of C3 fragments and other early activation 
products causes residual injury in Eculizumab-treated aHUS and DDD patients; 
however, in PNH patients treated with Eculizumab, C3 fragment opsonised 
erythrocytes are removed in spleen and liver, reducing circulating half-life 
(Risitano, et al., 2009). There would thus be some advantage in using therapies 
that target the AP convertase and switch off activation.  A recombinant human 
CR2/factor H fusion protein, TT30, has been developed that fits the bill and is in 
Phase I trials in PNH (Fridkis-Hareli, et al., 2011); its use in other AP 
dysregulation diseases, either alone or in combination with Eculizumab, is 
anticipated.  
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5) The complotype also impacts on infectious diseases. 
So far we have focused on the relevance of the complotype to acute or 
chronic inflammatory diseases; however, the principle role of complement is to 
kill invading bacteria so a role in infection is obvious.  While a complotype that 
provides a more active complement system will increase risk in inflammatory 
diseases, the opposite is true in infection where a more active complement 
system will more efficiently target pathogens and is thus protective.   Evidence 
in support of this is provided from comparison of complement polymorphisms in 
different populations; in communities at high risk of death from infection, for 
example, in Sub-Saharan Africans, there is a much higher frequency of 
polymorphisms that increase complement activity, a more active complotype, 
compared to low infection risk communities (Fridkis-Hareli, et al., 2011). A direct 
effect of the complotype on infection risk was revealed by a recent 
meningococcal disease GWAS (Davila, et al., 2010). A SNP in CFH (rs1065489; 
E936D) was identified where the D allele was protective for survival after 
infection.  The functional effect of this SNP is not yet clear, in part, because it is 
in strong LD with other SNPs along the CFH-CFHR3-CFHR1 region within CFH 
haplotype H3 (see above). Nevertheless, it is clear that polymorphisms in fH or 
FHRs influence risk of meningococcal disease by altering complement 
activation either in plasma or on the bacterial surface, possibly by altering 
function or relative expression levels of these key components. Although GWAS 
is a powerful way of identifying disease associations when allele frequency is 
high, linkage to less common polymorphisms can be missed and are only found 
when sought in a targeted manner.  For example, a regulator element 
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polymorphism in CFH, found by a targeted approach to be associated with 
meningococcal disease, caused altered plasma fH levels (Haralambous, et al., 
2006), while a polymorphism in complement C5 (rs17611;V802I), of unknown 
functional effect, was linked to poor outcome in bacterial meningitis (Woehrl, et 
al., 2011). 
 
Restoring homeostasis in diseases of complement dysregulation. 
Inter-individual differences in overall complement activity caused by the 
polymorphisms comprising the complotype are subtle, and even the disease-
linked complement protein mutations often cause relatively small changes in 
activity.  Impact of these small changes builds over time and hence many of the 
associated pathologies are chronic, evolving over years. Using drugs that 
completely block complement activation or effectors in these circumstances 
seems excessive. Except in acute episodes, complete inhibition of complement 
is not only unnecessary but is also potentially harmful, increasing risk of 
infection and other pathologies (Asghar and Pasch, 2000). The identification 
and characterization of protective disease-associated complement 
polymorphisms (Heurich, et al., 2011, Montes, et al., 2009, Tortajada, et al., 
2009) suggests that down-modulation without causing complete inhibition would 
be a measured and effective approach to an “over-active” complotype. In the 
case of HAE, drugs that cause relatively modest increases in plasma levels of 
C1inh, either by enhancing synthesis (anabolic steroids) or reducing 
consumption (protease inhibitors) are remarkably effective at preventing attacks 
(Cicardi and Zanichelli, 2010). Perhaps similar strategies to modestly increase 
plasma fH concentrations by enhancing production, supplementing with 
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exogenous protein or re-balancing the complex interplays with fHR proteins, will 
be effective, low-risk and affordable as prophylactic therapy for diseases like 
aHUS, DDD and AMD.  Knowledge of the complotype will guide such “fine 
tuning” approaches to the treatment of complement dysregulation.   
 
Conclusions. 
The complotype is a concept that will radically alter the way we consider 
the complement system and the way that complement contributes to disease.  It 
starts from the knowledge that individuals inherit very different complement 
systems that impact on their susceptibility to infections and risk of developing 
particular diseases. Advances in genomics and proteomics make it possible to 
assess an individual’s complotype and use this information for prediction of 
disease risk or outcome, counselling on behaviour modification and making 
decisions on therapies.  This patient-directed approach will enable better 
targeting of available drugs and guide future development of drugs tailor-made 
to redress the balance when complement is dysregulated. 
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Figure Legends. 
Figure 1. Activation and regulation of the complement system.  
Cleavage of C3 to generate C3b is the critical event in complement activation. 
The classical (CP) and lectin (LP) pathways involve recognition of target-bound 
antibody through C1q binding (CP), or pathogen-specific carbohydrates by MBL 
(LP). The associated protease units (C1s and MASP-2 respectively) then cleave 
C4 and C2, leading to formation of the C3 convertase C4b2a. In the alternative 
pathway (AP), continuous, low level, activation of C3 by spontaneous hydrolysis 
of the internal C3 thioester or cleavage by plasma proteases generates 
C3(H2O), a C3b-like molecule, or C3b, which can bind fB to form an AP 
convertase which cleaves C3 to C3b.  In the AP amplification loop (circle 
arrows), C3b, either membrane-bound or in the plasma, binds factor B (fB) 
generating additional AP C3 convertases that cleave many C3 molecules into 
C3b amplifying complement activation. The AP C3/C5-convertases are very 
labile enzymatic complexes (half-life of about 1min). However, binding of 
properdin (P) stabilises the enzyme, extending its half-life more than 10-fold.   
Activation of C3 by a membrane bound C3 convertase causes cluster 
deposition of C3b in the vicinity of the convertase. Incorporation of an additional 
C3b molecule to the C3 convertase creates a new enzyme, the C5 convertase, 
C3bBbC3b or C4b2a3b, which cleaves C5 to C5b and C5a. C5a is a highly 
proinflammatory polypeptide, whereas C5b initiates the formation of the lytic 
pore, the membrane attack complex (MAC) (terminal pathway). Complement 
homeostasis and protection of self-tissues from accidental complement attack is 
provided by proteins present in plasma and on cell membranes (boxes) which 
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either catalyze proteolytic inactivation of C3b/C4b by fI (MCP, CR1, fH, C4bp) 
or accelerate convertase dissociation (DAF, CR1, fH, C4bp). 
 
Figure 2. Mutations in fH found in aHUS and DDD patients. 
The location of most of the fH mutations thus far characterized in aHUS and  
DDD patients is indicated in a diagram of the structure of human fH showing the 
20 SCR repeats. The mutations associated with DDD are highlighted with a 
black box. Note that mutations associated with aHUS are clustered in the C-
terminus, the region of factor H that is critical for the control of C3b deposited on 
cell surfaces. 
 
Figure 3. Complement activation in different glomerulopathies. 
Schematic representation of the consequences of complement dysregulation in 
aHUS, where surface dysregulation results in strong C5 activation, and in DDD, 
where fluid phase activation primarily results in massive generation of C3b and 
iC3b.  In other C3-GN, the situation may vary depending on the proteins 
involved. 
 
Figure 4. CFHRs gene organization and structure of the FHRs proteins.  
A) Genomic organization of the CFH and CFHR1-5 genes. Arrows represent 
the genes with their names. Blue lines above the genes indicate the extent 
of linkage disequilibrium within three different SNP LD blocks. The coloured 
boxes underneath indicate the sequence repeats within this genomic 
region, labelled with the same letter (i.e., A, A’, A’’). The vertical lines 
indicate the positions of the exons of the CFH and CFHRs genes. 
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B) Structural organization of the fH and FHR proteins, including the FHR1*A 
and FHR1*B allotypes and the FHR4A and FHR4B isoforms. Short 
consensus repeats (SCRs) are represented by ovals and are numbered 
from the N-terminal end. Homologous SCRs are aligned and the amino acid 
differences from fH are indicated for SCR-3, -4, and -5 of FHR1*A and 
FHR1*B. Homologous SCRs are depicted with the same colour where they 
have greater than 80% amino acid identity. The colour code use in A to 
identify the different genomic sequence repeats has been maintained to 
correlate the SCR similarities with the genomic duplications. 
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TABLE 1. Risk factors associated with aHUS, C3-Glomerulopathies and AMD 
 
C3 Glomerulopathy 
 aHUS MPGN1, C3GN,fMPGN3 
CFHR5 nephropathy DDD 
AMD 
     
     
Genetic factors     
     
     
    - Mutations CFH 
MCP 
CFI 
CFB 
C3 
CFHR1 
THBD 
CFH 
CFI 
MCP 
CFHR5 
CFHR1 
CFH 
C3 
CFH 
 
 
    
   - Polymorphisms CFH 
MCP 
CFHR1 
CFHR3 
CFH 
CFHR1 
CFHR3 
CFHR5 
CFH 
CFHR1 
CFHR3 
CFHR5 
CFH 
CFI  
CFB 
C2 
C3 
C7 
CFHR1 
CFHR3 
AMRS2 (LOC387715) 
 
    
 
    
Autoantibodies Factor H C3Nef C3Nef, Factor H  
-  
    
 
    
Environmental 
factors 
Infection 
Immunosupp. drugs 
Cancer therapies 
Oral contraceptives 
 Pregnancy 
Childbirth, etc. 
Infection Infection Smoking 
Diet 
Exercise, etc. 
 
     
 
Table 1
 
 
TABLE 2. CFHRs gene rearrangements associated with disease. 
 
 
 
 
Disease Genetic findings Outcome Significance 
Risk/ 
Protection Prevalence Ref. 
CFH::CFHR1 
hybrid genes 
Substitution of the C-terminal 
SCRs of fH for those in FHR-1.  
Loss of complement 
regulation at cell surfaces. R 
Several 
unrelated cases 
described 
(Venables et al., 2006) 
CFH::CFHR3 
hybrid gene 
Substitution of the last C-
terminal SCR20 of fH for the 
whole FHR-3.  
Loss of complement 
regulation at cell surfaces R Very rare (Francis et al., 2012) 
DelCFHR3-CFHR1 
DelCFHR1-CFHR4 
Loss of FHR-3 and FHR-1. 
Loss of FHR-1 and FHR-4.  
Associated with auto anti 
fH antibodies impairing 
cell surface regulation.  
R Common 
(Abarrategui-Garrido et 
al., 2009; Moore et al., 
2010; Zipfel et al., 2007) 
aHUS 
 
 
 
 
 
 
 
 
 
 CFHR*B 
Allelic variant in which FHR-1 
SCR3 is identical to fH SCR18. Unknown R Common 
(Abarrategui-Garrido et 
al., 2009) 
DDD DupCFHR1 Mutant FHR-1 with SCR123412345 Unknown R Very rare 
(Abarrategui-Garrido et 
al., 2010) 
C3-GN CFHR3::CFHR1 hybrid gene 
Hybrid protein containing 
SCR1-2 of FHR-3 followed by 
the whole FHR-1 molecule. 
Unknown R Very rare (Malik et al., 2012) C
3 
G
lo
m
er
ul
op
at
hy
 
FHR5 
Nephropathy DupCFHR5 
Mutant FHR-5 with 
SCR12123456789 Unknown R 
Several related 
cases described (Gale et al., 2010) 
AMD 
 
 
DelCFHR3-CFHR1 
 
CFHR*A 
 
 
 
Loss of FHR-3 and FHR-1. 
 
Allelic variant in which FHR-1 
SCR3 differs from fH SCR18 in 
three amino acids. 
 
Unknown 
 
Unknown 
 
 
 
P 
 
R 
 
 
 
Common 
 
Common 
 
 
 
(Hughes et al., 2006) 
 
(Martinez-Barricarte et 
al., 2012) 
 
SLE 
 
DelCFHR3-CFHR1 
 
Loss of FHR-3 and FHR-1.  Unknown R Common (Zhao et al., 2011) 
Table 2
We have revised the manuscript in response to the helpful comments of the reviewers.  We have up-
dated figure 2 to include recently described mutations. We have replaced Figure 4 with a modified, 
clearer version, we have added text in several places (highlighted in submitted Ms) to address 
omissions noted in review. We have added four additional references in response to reviewer 
comments. 
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